Advanced Breast Cancer Clinical Trial
— HERMIONE-13Official title:
Multicenter Retrospective Observational (Descriptive) Study of Second-line Therapies After Progression to CDK4/6i in Association With Hormone Therapy, in Patients With HR+/HER2- Advanced Breast Cancer (HERMIONE 13)
Description of the choices for second line treatment, in the normal clinical practice of the centers adhering to the Hermione Network, in patients affected by advanced HR+/HER2- breast cancer who progressed after CDK4/6i in association with hormonal therapy.
Status | Recruiting |
Enrollment | 150 |
Est. completion date | January 30, 2024 |
Est. primary completion date | January 30, 2024 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - age> 18 years - female sex - Performance Status (ECOG) 0-2; - hormonal-receptor positive breast cancer (Estrogen and / or Progesterone positive), HER2 negative, with evidence of stage IV / locally advanced inoperable disease - Radiologically documented progression in 1st line treatment with Hormonal Therapy (Aromatase inhibitor / Fulvestrant) + CDK4-6i (Palbociclib / Ribociclib / Abemaciclib) - Execution of at least one subsequent therapeutic line chosen by the clinician, with at least one radiological re-evaluation during this treatment by 31 December 2020. - Radiologically measurable or evaluable lesions - Written informed consent Exclusion Criteria: - age <18 years - previous neoplastic pathology, within 5 years of the last active treatment - Previous chemotherapy treatments, with biological or endocrine therapies for advanced disease, different from first-line therapy with OT + CDK4 / 6i |
Country | Name | City | State |
---|---|---|---|
Italy | Clinica Oncologica Aou Ospedali Riuniti | Ancona | |
Italy | Ospedale Cardinal Massaia Asti | Asti | |
Italy | Ospedale San Martino | Belluno | |
Italy | OSPEDALE Sacro Cuore di Gesù - Fatebenefratelli | Benevento | |
Italy | Spedali Civili Brescia | Brescia | |
Italy | Ospedale Sant'Anna, San Fermo della Battaglia | Como | |
Italy | ASST Cremona - Area Donna | Cremona | |
Italy | ASST VALLE OLONA - Presidio Gallarate - SC Oncologia | Gallarate | |
Italy | A.S.S.T. Ovest Milanese | Legnano | |
Italy | Ospedale Civile di Livorno, Azienda USL Toscana Nord Ovest | Livorno | |
Italy | ISTITUTO ROMAGNOLO per la cura e lo studio dei tumori (IRST-IRCCS) | Meldola | |
Italy | ASST Fatebenefratelli Sacco | Milano | |
Italy | Policlinico di Milano Ospedale Maggiore, Fondazione IRCCS Ca' Granda | Milano | |
Italy | Ospedale San Gerardo | Monza | |
Italy | UO Aziendale Olbia | Olbia | |
Italy | Ospedale La Maddalena | Palermo | |
Italy | ICS Maugeri Spa-SB PAVIA | Pavia | |
Italy | U.O.C Oncologia Ospedale "G Da Saliceto" | Piacenza | |
Italy | UO Oncologia Medica I Azienda Ospedaliero Universitaria Pisana | Pisa | |
Italy | Azienda USL - Arcispedale S. Maria Nuova IRCCS | Reggio Emilia | |
Italy | A.S.S.T. Rhodense Ospedale Di Circolo Rho | Rho | |
Italy | Oncologia Ospedale di Rimini | Rimini | |
Italy | IRCCS Istituto Nazionale Tumori - IFO Regina Elena, Oncologia Medica B | Roma | |
Italy | Policlinico Gemelli | Roma | |
Italy | AOU città della scienza e della salute SCDO4 | Torino | |
Italy | AOU città della scienza e della salute SCDU1 | Torino | |
Italy | Oncologia Trento | Trento | |
Italy | PIA FONDAZIONE Cardinale PANICO Tricase - Lecce | Tricase | |
Italy | ASST SETTELAGHI - Oncologia Varese | Varese |
Lead Sponsor | Collaborator |
---|---|
University of Milano Bicocca |
Italy,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Description of the choices for second line treatment in patients affected by advanced HR+/HER2- breast cancer who progressed after CDK4/6i in association with hormonal therapy. | Description of the choices for second line treatment, in the normal clinical practice of the centers adhering to the Hermione Network, in patients affected by advanced HR+/HER2- breast cancer who progressed after CDK4/6i in association with hormonal therapy. | Entire study duration, approximately 12 months | |
Secondary | progression-free survival | time from the start of treatment to evidence of disease progression or death | from date of treatment beginning until the date of first documented progression or date of death from any cause, assessed up to 72 months | |
Secondary | response rate | radiological response rate according to RECIST criteria, classified as CR (Complete Response), PR (Partial Response), SD (Stable Disease), PD (Progressive Disease) | Entire study duration, approximately 12 months | |
Secondary | Survival Post Progression | survival evaluated from from date of treatment beginning until the date of first documented progression or date of death from any cause | from date of treatment beginning until the date of first documented progression or date of death from any cause, assessed up to 72 months | |
Secondary | progression by location (visceral versus non-visceral). | time from the date second-line treatment beginning to the date of disease progression or death from any cause, stratified according to visceral versus non-visceral diseaes | from date of treatment beginning until the date of first documented progression or date of death from any cause, assessed up to 72 months | |
Secondary | Drug toxicities | Evaluation of drug related toxicities listed according to the different therapeutic options | Entire study duration, approximately 12 months | |
Secondary | Physician's reasons for treatment choice in real world experience | Evaluation of the physician's reasons for treatment choice of the second-line therapy after progression to CDK4 / 6i associated with hormonal therapy | Entire study duration, approximately 12 months | |
Secondary | Predictive factors of response | Evaluation of predictive factors of response through the comparison of four variables according to AIC e R2 criteria | Entire study duration, approximately 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04653740 -
Omic Technologies to Track Resistance to Palbociclib in Metastatic Breast Cancer
|
N/A | |
Completed |
NCT02091960 -
A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Locally Advanced Breast Cancer
|
Phase 2 | |
Recruiting |
NCT05156619 -
Health Care Disparities in Culturally Diverse, Special Needs & Disadvantaged Populations - Bridging the Gap
|
||
Withdrawn |
NCT05191004 -
Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC
|
Phase 1/Phase 2 | |
Completed |
NCT00754325 -
Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor
|
Phase 2 | |
Recruiting |
NCT04953377 -
PFMT Educational Intervention for Patients With Advancer Breast Cancer
|
N/A | |
Completed |
NCT03240224 -
Bioinformation Therapy for Breast Cancer
|
Phase 2/Phase 3 | |
Recruiting |
NCT06193525 -
FUnctional Selection of Advanced Breast Cancer Patients for Talazoparib Treatment Using the REpair Capacity (RECAP) Test
|
Phase 2 | |
Completed |
NCT03312738 -
A Study of Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase Inhibitor
|
Phase 2 | |
Active, not recruiting |
NCT05063786 -
Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET)
|
Phase 3 | |
Recruiting |
NCT05655598 -
TAS-116 Plus Palbociclib in Breast and Rb-null Cancer
|
Phase 1 | |
Active, not recruiting |
NCT02499146 -
Palbociclib Pharmacokinetics Study In Postmenopausal Chinese Women With ER (+), HER2 (-) Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT00445458 -
A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT04456855 -
Locoregional Surgery of the Primary Tumor in de Novo Stage IV Breast Cancer Patients
|
||
Completed |
NCT04408118 -
First Line Atezolizumab, Paclitaxel, and Bevacizumab (Avastin®) in mTNBC
|
Phase 2 | |
Recruiting |
NCT04222413 -
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
|
Phase 1 | |
Completed |
NCT03205761 -
Analysis of Olaparib Response in Patients With BRCA1 and/or 2 Promoter Methylation Diagnosed of Advanced Breast Cancer
|
Phase 2 | |
Withdrawn |
NCT04316169 -
Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive (HR+)/Her 2 Negative Breast Cancer
|
Phase 1 | |
Completed |
NCT00546104 -
Phase II Dasatinib Study in Advanced Breast Cancer
|
Phase 2 | |
Completed |
NCT00387907 -
Study of Larotaxel in Combination With Weekly Herceptin® in Patients With HER2 Positive Metastatic Breast Cancer
|
Phase 2 |